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The membrane receplor Iyrosine kinases (RTKs), possess bolh exlracellular and inlracellular domains 
and seleclively calalyze the phosphorylation 01 Iyrosine hydroxyl groups in response lo binding 01 
certain exlracellular growlh faclors. RTK signalling palhways are normally highly regulaled, yel Iheir 
over-activation has been shawn to promete the growth, survival, and metastasis of cancer cells, and 
has been associaled wilh lhe progression 01 various human cancers. Recently some thieno[3,2-
c]pyridine 1,3-diarylurea derivatives were prepared as VEGFR-2 (vascular endothelium growth factor 
receptor-2) inhibitors.' Here we present the synthesis of methyl 3-amino-6-[4 or 3 ar 2-(3-
arylureido)phenyl]lhieno[3,2-b]pyridine-2-carboxylates 2 by reaction of the methyl 3-amino-6-(4 or 3 or 
2-aminophenyl)thieno[3,2-b]pyridine-2-carboxylates 1, synthesized earlier by our group,2 with 
arylisocyanates (Scheme). 
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(9 compounds, 85-95%) 
Scheme 
Compounds 2 were evaluated as potential VEGFR-2 inhibitors using AutoDoek Vina as molecular 
docking software. The enzyme X-ray 3-D struelure was obtained Irom lhe Protein Data Bank: VEGFR2 
(POB: 1YWN) and the estimated inhibition constants (Ki) 01 the synthesised compounds were 
obtained . ln order to val idate the molecular docking approach, the respective co-crystallized ligand 
(LlF) and Soralenib, a known drug that inhibit VEGFR2, were docked to the kinase domain. The 
difference between the X-ray conlormation and the predicted docked conlormations 01 both ligands as 
well as the difference between estimated Ki (Soralenib: 109 nM; LlF: 7 nM) and experimental Ki 
(Soralenib: 93 nM3 , LlF : 2 nM') were negligible, validating the protein structures for virtual screening 
with the synthesised compounds. The potential use 01 the compounds as luture drugs was studied by 
applying the Lipinski's Rule 01 Five analysis and it was observed that ali compounds respected this 
rule.Comparing the Ihree compounds of the Ihree different substituted positions , lhe besl results lor Ki 
were observed for the compounds 2 with R = H when lhe amino group was in the 2 ar 3-position in 
compounds 1 (214 and 180 nM, respectively) while when lhe amino group was in the 4-position 01 
compounds 1 lhe best compound 2 was the one wilh R = OMe (253 nM). 
Moreover, lhe docking pose 01 the compounds wilh lhe besl docking score was analyzed in arder lo 
understand the key inleraclions belween the compounds and lhe VEGFR-2 kinase domain structure. 
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